» Articles » PMID: 34222711

Pediatric Nonalcoholic Fatty Liver Disease and the Microbiome: Mechanisms Contributing to Pathogenesis and Progression

Overview
Specialty Endocrinology
Date 2021 Jul 5
PMID 34222711
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common form of pediatric liver disease in the United States, and often associated with obesity and metabolic syndrome. NAFLD comprises a broad spectrum of liver diseases, from hepatic steatosis to steatohepatitis, fibrosis and cirrhosis. Disease progression is considered a multi-modal process of liver injury. The intestinal microbiome has been implicated in several aspects of NAFLD pathophysiology. Pediatric studies associating the intestinal microbiome with NAFLD have been limited in number and complicated by inconsistencies in study design and approach. Nevertheless, they provide support for involvement of the intestinal microbiome in NAFLD development and progression and point to common mechanisms shared by microbiome-associated inflammatory diseases with potential to inform future therapeutic intervention.

Citing Articles

Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives.

Vimalesvaran S, Vajro P, Dhawan A Hepatol Int. 2024; 18(Suppl 2):873-883.

PMID: 38879851 PMC: 11450008. DOI: 10.1007/s12072-024-10691-5.


Gut Microbiota and Microbial Metabolism in Early Risk of Cardiometabolic Disease.

Gabriel C, Ferguson J Circ Res. 2023; 132(12):1674-1691.

PMID: 37289901 PMC: 10254080. DOI: 10.1161/CIRCRESAHA.123.322055.

References
1.
Day C, James O . Steatohepatitis: a tale of two "hits"?. Gastroenterology. 1998; 114(4):842-5. DOI: 10.1016/s0016-5085(98)70599-2. View

2.
Marietta E, Mangalam A, Taneja V, Murray J . Intestinal Dysbiosis in, and Enteral Bacterial Therapies for, Systemic Autoimmune Diseases. Front Immunol. 2020; 11:573079. PMC: 7655733. DOI: 10.3389/fimmu.2020.573079. View

3.
Zakhari S . Overview: how is alcohol metabolized by the body?. Alcohol Res Health. 2007; 29(4):245-54. PMC: 6527027. View

4.
Boursier J, Diehl A . Nonalcoholic Fatty Liver Disease and the Gut Microbiome. Clin Liver Dis. 2016; 20(2):263-75. DOI: 10.1016/j.cld.2015.10.012. View

5.
Fan Y, Pedersen O . Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2020; 19(1):55-71. DOI: 10.1038/s41579-020-0433-9. View